Author(s):
Anuradha G. More, Dhanashri P. Garud
Email(s):
anuradhagmore2011@gmail.com
DOI:
10.52711/0974-360X.2026.00199 
Address:
Anuradha G. More1*, Dhanashri P. Garud2
1P.E. Society’s Modern College of Pharmacy, Nigdi, Pune - 411044, Maharashtra, India.
2P.E. Society’s Modern College of Pharmacy, SPPU, Pune - 411044, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 3,
Year - 2026
ABSTRACT:
Breast cancer is the most prevalent solid malignant tumor worldwide, affecting 2.26 million women, with approximately 685,000 deaths from the disease, as estimated on an annual basis by the World Health Organization. About 60-80% of invasive breast cancer in postmenopausal women are estrogen or hormone-receptor-positive breast tumors. Endocrine therapy is a cornerstone for treating hormone receptor-positive breast cancer and includes selective estrogen receptor modulators like Tamoxifen and aromatase inhibitors. Besides the therapeutic effects of hormonal therapy, challenges such as osteoporosis induced by aromatase inhibitors, drug resistance, and recurrence complicate the management of breast cancer. Consequently, there is a significant demand for practical approaches to overcome resistance to endocrine therapy and prevent breast cancer metastasis. This article focuses on therapy for estrogen-positive breast cancer and its adverse impact on patient quality of life. It also examines strategies to reduce side effects by combining natural sources with nanocarriers to enhance therapeutic effects and minimize side effects. It also reviews ongoing research aimed at improving outcomes for patients with hormone-positive breast cancer.
Cite this article:
Anuradha G. More, Dhanashri P. Garud. Challenges and Emerging Strategies for Aromatase Inhibitors in Postmenopausal Breast Cancer Treatment. Research Journal Pharmacy and Technology. 2026;19(3):1383-9. doi: 10.52711/0974-360X.2026.00199
Cite(Electronic):
Anuradha G. More, Dhanashri P. Garud. Challenges and Emerging Strategies for Aromatase Inhibitors in Postmenopausal Breast Cancer Treatment. Research Journal Pharmacy and Technology. 2026;19(3):1383-9. doi: 10.52711/0974-360X.2026.00199 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-60
REFERENCES:
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. A Cancer Journal for Clinicians 2021; 71(3): 209-249. doi:10.3322/caac.21660
2. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66: 15-23. doi:10.1016/j.breast.2022.08.010
3. García-Sánchez J, Mafla-España MA, Torregrosa MD, Cauli O. Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study. Breast. 2022; 66: 310-316. doi:10.1016/j.breast.2022.11.007
4. Yap KM, Sekar M, Fuloria S, et al. Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature. International Journal of Nanomedicine. 2021; 16: 7891-7941. Published 2021 Dec 2. doi:10.2147/IJN.S328135
5. van Dyk L, Verhoog NJD, Louw A. Combinatorial treatments of tamoxifen and SM6Met, an extract from Cyclopia subternata Vogel, are superior to either treatment alone in MCF-7 cells. Frontiers in Pharmacology. 2022; 13: 1017690. Published 2022 Sep 22. doi:10.3389/fphar.2022.1017690
6. Choi SH, Kim KE, Park Y, et al. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Breast. 2020; 54: 25-30. doi:10.1016/j.breast.2020.08.003
7. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International Journal of Clinical Practice. 2007; 61(12): 2051-2063. doi:10.1111/j.1742-1241.2007.01587.x
8. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone. 2007; 40(1): 205-210. doi:10.1016/j.bone.2006.06.027
9. Eissa AG, Barrow D, Gee J, Powell LE, Foster PA, Simons C. 4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors. European Journal of Medicinal Chemistry. 2022; 240: 114569. doi:10.1016/j.ejmech.2022.114569
10. Moudgil A, Salve R, Gajbhiye V, Chaudhari BP. Challenges and emerging strategies for next generation liposomal based drug delivery: An account of the breast cancer conundrum. Chemistry and Physics of Lipids. 2023; 250: 105258. doi:10.1016/j.chemphyslip.2022.105258
11. Vieira C, Piperis MN, Sagkriotis A, Cottu P. Systemic treatment for hormone receptor-positive/ HER2-negative advanced/ metastatic breast cancer: A review of European real-world evidence studies. Critical Reviews in Oncology/ Hematology. 2022; 180: 103866. doi:10.1016/j.critrevonc.2022.103866
12. Bishoyi B, Jaiswal H, Shah Y, Dikkatwar M, Bindu R. Early detection and Advanced Targeted Drug Therapies for HER2 positive breast cancer. Research Journal of Pharmacy and Technology. 2023; 16(5): 2205-9. doi: 10.52711/0974-360X.2023.00362
13. Wahyuni, Diantini A, Ghozali M, Sahidin I. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology. 2022; 15(1): 409-8. doi: 10.52711/0974-360X.2022.00068
14. Dhania N, Riris IJ, Febri W, Rohmad YU, et al. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. Research Journal of Pharmacy and Technology. 2021; 14(8): 4375-2. doi: 10.52711/0974-360X.2021.00760
15. Ferrari P, Nicolini A. Overcoming Endocrine Resistance in Breast Cancer : mTOR Inhibitors and New Drugs. Oncogenomics. Elsevier Inc.; 2019. 391–420 doi:http://dx.doi.org/10.1016/B978-0-12-811785-9.00029-6
16. Oh SH, Nam BR, Lee IS, Lee JH. Prolonged anti-bacterial activity of ion-complexed doxycycline for the treatment of osteomyelitis. European Journal of Pharmaceutics and Biopharmaceutics. 2016; 98: 67–75. doi: http://dx.doi.org/10.1016/j.ejpb.2015.11.006
17. Kalam A, Talegaonkar S, Vohora D. Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Molecular and Cellular Endocrinology . 2017; 440: 34-43. doi:10.1016/j.mce.2016.11.005
18. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. International Journal of Molecular Sciences. 2023; 24(7): 6834. Published 2023 Apr 6. doi:10.3390/ijms24076834.
19. Sun YS, Zhao Z, Yang ZN, et al. Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences. 2017; 13(11): 1387-1397. Published 2017 Nov 1. doi:10.7150/ijbs.21635
20. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011; 76(8): 812-815. doi:10.1016/j.steroids.2011.02.029
21. Khan MZI, Uzair M, Nazli A, Chen JZ. An overview on Estrogen receptors signaling and its ligands in breast cancer. European Journal of Medicinal Chemistry. 2022; 241: 114658. doi:10.1016/j.ejmech.2022.114658
22. Xu J, Cao B, Li C, Li G. The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy. Frontiers in Oncology. 2023; 13: 1218206. Published 2023 Jul 7. doi:10.3389/fonc.2023.1218206.
23. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. Journal of Bone Oncology. 2021; 28: 100355. Published 2021 Mar 18. doi:10.1016/j.jbo.2021.100355.
24. Trémollieres FA. Trémollieres FA. Screening for osteoporosis after breast cancer: for whom, why and when. Maturitas. 2014; 79(3): 343-348. doi:10.1016/j.maturitas.2014.08.001.
25. Padmanabhan K, Paul J, Sudhakar S, Senthil Selvam P, Sathya Priya V, Veena Kirthika S. Which is more prevalent among the female population - Osteopenia or Osteoporosis? A cross sectional study. Research Journal of Pharmacy and Technology. 2019; 12(3): 1163-1168. doi: 10.5958/0974-360X.2019.00192.6
26. Muhammad A, Mada SB, Malami I, et al. Postmenopausal osteoporosis and breast cancer: The biochemical links and beneficial effects of functional foods. Biomedicine and Pharmacotherapy. 2018; 107: 571-582. doi:10.1016/j.biopha.2018.08.018
27. Gao Y, Chen N, Fu Z, Zhang Q. Progress of Wnt Signaling Pathway in Osteoporosis. Biomolecules. 2023; 13(3): 483. Published 2023 Mar 6. doi:10.3390/biom13030483
28. Vohora D, Kalam A, Leekha A, Talegaonkar S, Verma AK. Combined Raloxifene and Letrozole for Breast Cancer Patients. Archives of Medical Research. 2017; 48(6): 561-565. doi:10.1016/j.arcmed.2017.11.012
29. Goyal A, Gupta JK, Garabadu D. Phytoestrogens are emerging medicine in Prevention and Management of Cognitive deficits in Postmenopausal Women. Research Journal of Pharmacy and Technology. 2021; 14(1): 513-515. doi: 10.5958/0974-360X.2021.00093.7.
30. Ahmed HH, Aglan HA, Elsayed GH, Hafez HG, Eskander EF. Quercetin Offers Chemopreventive Potential against Breast Cancer by Targeting a Network of Signalling Pathways. Research Journal of Pharmacy and Technology. 2021; 14(5) doi: 10.52711/0974-360X.2021.00499.
31. Ahirwar B, Ahirwar D. In vivo and in vitro investigation of cytotoxic and antitumor activities of polyphenolic leaf extract of Hibiscus sabdariffa against, breast cancer cell lines. Research Journal of Pharmacy and Technology. 2019; 13(2): 615-620. doi: 10.5958/0974-360X.2020.00116.X
32. Tanwar AK, Dhiman N, Kumar A, Jaitak V. Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. European Journal of Medicinal Chemistry. 2021; 213: 113037. doi:10.1016/j.ejmech.2020.113037
33. Mondal R, Dey D, Maity S, Giri TK. Recent advancement of Ionic polysaccharide-based nanoparticles for Cancer therapy. Research Journal of Pharmacy and Technology. 2021; 14(2): 1122-1130. doi: 10.5958/0974-360X.2021.00202.X.
34. Sartaj A, Annu, Biswas L, et al. Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization. BioMed Research International. 2022; 2022: 6009309. Published 2022 Feb 3. doi:10.1155/2022/6009309
35. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharmaceutical Nanotechnology. 2019; 7(1): 3-23. doi:10.2174/2211738507666190122111224
36. Poschner S, Wackerlig J, Dobusch D, et al. Actaea racemosa L. extract inhibits steroid sulfation in human breast cancer cells: Effects on androgen formation. Phytomedicine. 2020; 79: 153357. doi:10.1016/j.phymed.2020.153357
37. Fang Z, Li X, Xu Z, et al. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery. International Journal of Nanomedicine 2019; 14: 5785-5797. Published 2019 Jul 30. doi:10.2147/IJN.S213974
38. Han NK, Shin DH, Kim JS, Weon KY, Jang CY, Kim JS. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. International Journal of Nanomedicine. 2016; 11: 1413-1425. Published 2016 Apr 5. doi:10.2147/IJN.S95850
39. Meng F, Liu F, Lan M, Zou T, Li L, Cai T, et al. Preparation and evaluation of folate-modified albumin baicalin-loaded nanoparticles for the targeted treatment of breast cancer. Journal of Drug Delivery Science and Technology 2021; 65: 102603. doi:10.1016/j.jddst.2021.102603
40. Cé R, Couto GK, Pacheco BZ, et al. Folic acid-doxorubicin polymeric nanocapsules: A promising formulation for the treatment of triple-negative breast cancer. European Journal of Pharmaceutical Sciences 2021; 165: 105943. doi:10.1016/j.ejps.2021.105943
41. Sinai Kunde S, Wairkar S. Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation. International Journal of Pharmaceutics 2022; 623: 121926. doi:10.1016/j.ijpharm.2022.121926
42. Gaber M, Hany M, Mokhtar S, Helmy MW, Elkodairy KA, Elzoghby AO. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Materials Science and Engineering: C. 2019; 105: 110099. doi:10.1016/j.msec.2019.110099
43. Salsa LA, Tri W, Suko H, Bambang TP. QSAR of Acyl pinostrobin derivatives as Anti-breast cancer against HER-2 receptor and their ADMET properties based on in silico Study. Research Journal of Pharmacy and Technology. 2022; 15(10): 4641-8. doi: 10.52711/0974-360X.2022.00779
44. Jainab NH, Mohan MK. In Silico Molecular Docking Studies on the Chemical Constituents of Clerodendrum phlomidis for its Cytotoxic Potential against Breast Cancer Markers. Research Journal of Pharmacy and Technology. 2018; 11(4): 1612-1618. doi: 10.5958/0974-360X.2018.00300.1